Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Work with your provider to find the optimal approach for your stage of treatment
GLP1-S is a synthetic peptide analog of the incretin hormone glucagon-like peptide-1 (GLP-1)
The EMA PRAC 2024 review found no causal link between licensed GLP-1 receptor agonists and suicidal ideation or self-harm, but this conclusion cannot be directly applied to retatrutide, which has additional glucagon receptor activity and lacks its own long-term safety data
Why energy changes often resurface when increasing your dose Even if you felt great on a 2.5mg dose, moving to 5mg or 7.5mg introduces a stronger signal to your system
Common Side Effects Common side effects include: Nausea Diarrhea Vomiting Constipation Stomach pain Decreased appetite Headache Serious Side Effects (Less Common) While serious side effects are rare, they may include: Pancreatitis (inflammation of the pancreas) Gallbladder problems Kidney injury due to dehydration from nausea or vomiting Serious allergic reactions Vision changes in type 2 diabetes patients Increased heart rate Oral semaglutide has a boxed warning for potential thyroid C-cell tumors, as observed in animal studies, and is not recommended for those with a history of medullary thyroid carcinoma
Adapting to the Appetite Shift: Food Industry Strategies Amid the Rise of GLP-1 Drugs According to the World Obesity Federation (2024), estimates for global levels of obesity (high BMI) suggest that nearly 3.3 billion adults may be affected by 2035, compared with 2.2 billion in 2020
